Key Considerations When Selecting EGFR Inhibitor Treatments in NSCLC
Zosia Piotrowska, MD, MHS, and Martin Dietrich, MD, PhD, discuss how the treatment landscape for EGFR-mutated non–small cell lung cancer (NSCLC) has evolved from osimertinib monotherapy toward combination approaches, with experts weighing efficacy benefits against toxicity profiles while emphasizing the importance of individualized treatment selection, prophylactic toxicity management, and careful consideration of subsequent therapy options after disease progression.
EP. 1: Combination Therapy: A New Frontline Standard in the Treatment of EGFR-Mutant NSCLC
April 28th 2025Panelists discuss how the treatment landscape for EGFR-mutant non–small cell lung cancer has evolved with new combination therapies like osimertinib plus chemotherapy (FLAURA2) and amivantamab plus lazertinib (MARIPOSA) challenging osimertinib monotherapy as the standard of care.
EP. 3: Analyzing the MARIPOSA Overall Survival Data in the Frontline Treatment of EGFR-Mutant NSCLC
May 9th 2025Panelists discuss how the overall survival benefit from the MARIPOSA regimen (amivantamab plus lazertinib) with a hazard ratio of 0.75 and projected survival improvement exceeding 1 year represents a significant advancement that must be weighed against toxicity concerns.
EP. 4: The Importance of Quality of Life in Treatment Decision-Making for EGFR-Mutant NSCLC
May 9th 2025Panelists discuss how quality of life considerations, including prophylactic medications to prevent dermatologic toxicities and infusion-related reactions, are crucial when implementing EGFR-targeted therapies, especially the MARIPOSA regimen.
EP. 6: The Impact of Frontline Treatment Selection on Second-line Therapy for EGFR-mutant NSCLC
May 16th 2025Panelists discuss how many patients never receive second-line therapy, emphasizing the critical importance of selecting the optimal first-line treatment and monitoring patients closely to identify progression early.
EP. 7: Treatment Options in the Second-Line for CNS Protection In EGFR-Mutant NSCLC
May 23rd 2025Panelists discuss how central nervous system (CNS) progression presents unique challenges in treatment decision-making, highlighting the importance of brain imaging surveillance and considering approaches that maintain CNS disease control while addressing systemic progression.
